Biscayne Pharma

Miami, United States Founded: 2012 • Age: 14 yrs Acquired By Supernus Pharmaceuticals
Clinical-stage drugs for CNS disorders and drug-resistant cancers are developed.
Annual revenue - Latest available
Total funding $10.5M 5 rounds
Employees - Tracked headcount
Investors 5 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Biscayne Pharma

Biscayne Pharma is a company based in Miami (United States) founded in 2012 was acquired by Supernus Pharmaceuticals in September 2018. Biscayne Pharma has raised $10.53 million across 5 funding rounds from investors including Supernus Pharmaceuticals, GF Securities and Quark Venture. Biscayne Pharma offers products and services including Health Blogs and Supplements Information.

  • Headquarter Miami, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $10.53 M (USD)

    in 5 rounds

  • Latest Funding Round
    $3 M (USD), Series B

    Jan 27, 2017

  • Investors
  • Employee Count
    Not available
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Biscayne Pharma

Biscayne Pharma offers a comprehensive portfolio of products and services, including Health Blogs and Supplements Information.

Product name locked
Category locked
Primary

Delivers articles on wellness, meditation, and health tips.

Product name locked
Category locked
Locked

Provides details on supplements like CBD oil and pain relief options.

Funding Insights of Biscayne Pharma

Biscayne Pharma has successfully raised a total of $10.53M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $3 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Biscayne Pharma

Biscayne Pharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Supernus Pharmaceuticals, GF Securities and Quark Venture.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech & Life Sciences focused early stage VC firm investing in North America
Locked Locked Locked
-
Locked Locked Locked
Provider of investment & asset management and financial services
Locked Locked Locked
Premium access

Investor details for Biscayne Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Biscayne Pharma

Investments
Premium access

Investment portfolio details for Biscayne Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Biscayne Pharma

Premium access

Detailed financials for Biscayne Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Biscayne Pharma Comparisons

Biscayne Pharma Primary company
Description
Clinical-stage drugs for CNS disorders and drug-resistant ca...
Location
Miami, United States
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Biscayne Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Biscayne Pharma

Premium access

Detailed competitors of Biscayne Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Biscayne Pharma

Premium access

Complete news archive for Biscayne Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Biscayne Pharma

Biscayne Pharma was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Biscayne Pharma is headquartered in Miami, United States. It is registered at Miami, Florida, United States.

Biscayne Pharma is a funded company, having raised a total of $10.53M across 5 funding rounds to date.

Biscayne Pharmaceuticals is a clinical stage drug development biotech focusing on CNS disorders (refractory epilepsy) and drug-resistant cancer. Biscayne acquired the CNS program, and the molecule BIS-001, as part of its merger with Insero Health in 2015. BIS-001, which has completed Phase I clinical studies, is an acetylcholinesterase inhibitor. The pipelines for cancer (BIS-1602 - Breast, endometrial, ovarian cancers) and cardiology are based on Growth hormone Releasing Hormone (GHRH) - based on Nobel Laureate Biscayne co-founder, Dr. Andrew Schallys research.

Biscayne Pharma offers Health Blogs and Supplements Information.

Biscayne Pharma has 5 investors. Key investors include Supernus Pharmaceuticals, GF Securities, Quark Venture, Mesa Verde Venture Partners, and Florida Institute.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available